| Cancer pharmacogenomics: international trends. | |
| | |
MedLine Citation:
|
PMID: 15729594 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
It is well known that inter-individual variability exists in the responses to many drugs. Many nongenetic factors, such as age, sex, diet, and organ function, are known to affect the therapeutic effects of drugs. However, recent advances in pharmacogenomics have revealed that genetic polymorphisms also significantly influence both the efficacy and the toxicity of drugs. Mutations in the genes encoding drug-metabolizing enzymes, transporters, and target molecules may alter their expression, activity, or affinity to drugs, thereby influencing the drugs' pharmacokinetics and pharmacodynamics. Numerous studies have reported on the correlations between therapeutic outcomes and polymorphisms in drug-metabolizing enzymes, transporters, target molecules, and DNA repair enzymes. These pharmacogenomic discoveries are expected to be useful for the individualization and optimization of cancer chemotherapy. |
| | |
Authors:
|
Yasuko Yamayoshi; Emiko Iida; Yusuke Tanigawara |
Related Documents
:
|
20305604 - The role of cyp2d6 and taqi a polymorphisms in malignant neuroleptic syndrome: two case... 14515604 - The variation of response to pharmacotherapy: pharmacogenetics--a new perspective to 't... 12570744 - Drug metabolism and individualized medicine. 18448784 - A preliminary attempt to personalize risperidone dosing using drug-drug interactions an... 19785064 - Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm... 15558194 - Photocytotoxicity of a 5-nitrofuran-ethenyl-quinoline antiseptic (quinifuryl) to p388 m... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: International journal of clinical oncology Volume: 10 ISSN: 1341-9625 ISO Abbreviation: Int. J. Clin. Oncol. Publication Date: 2005 Feb |
Date Detail:
|
Created Date: 2005-02-24 Completed Date: 2005-05-24 Revised Date: 2012-12-13 |
Medline Journal Info:
|
Nlm Unique ID: 9616295 Medline TA: Int J Clin Oncol Country: Japan |
Other Details:
|
Languages: eng Pagination: 5-13 Citation Subset: IM |
Affiliation:
|
Department of Hospital Pharmacy, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
pharmacology,
therapeutic use Cytochrome P-450 Enzyme System / genetics, pharmacology DNA Damage DNA Repair Glucuronosyltransferase / genetics, pharmacology Humans International Cooperation Methylenetetrahydrofolate Reductase (NADPH2) / genetics, pharmacology Methyltransferases / genetics, pharmacology Neoplasms / drug therapy*, genetics* Pharmacogenetics / trends* Polymorphism, Genetic |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 9035-51-2/Cytochrome P-450 Enzyme System; EC 1.5.1.20/Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.1.-/Methyltransferases; EC 2.1.1.67/thiopurine methyltransferase; EC 2.4.1.17/Glucuronosyltransferase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Identification of proteins interacting with Toxoplasma SRCAP by yeast two-hybrid screening.
Next Document: Cancer pharmacogenomics: achievements in basic research.